BioCentury
ARTICLE | Company News

Mero licenses AAT deficiency candidate from AstraZeneca

December 8, 2017 2:53 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Mereo BioPharma Group plc (LSE:MPH) an exclusive license and option to acquire AZD9668, an oral inhibitor of neutrophil elastase (ELANE; NE; HLE) which is...